Extensive research indicates that nonfunctional mutated p53 significantly contributes to tumor initiation and progression, correlating with poor clinical outcomes, reduced survival rates, unfavorable prognosis, and chemotherapy resistance in oncology patients [80,81,82]. Here, TP53 is linked to neoplasm.